In 274 patients with resected ALK-positive stage IB–IIIB NSCLC after adjuvant chemotherapy, 24 months of ensartinib vs placebo raised 24-month disease-free survival in stage II–IIIB disease (86.4% vs 53.5%; HR 0.20). Grade ≥3 adverse events: 35.8% vs 18.2%.
RCTn = 274
Yue et al. Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer